Valeant Pharmaceuticals (VRX) Reiterated Top Pick at Mizuho Securities; PT to $111
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week
November 23, 2015 10:43 AM ESTShort seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:
Citi launched coverage on the... MoreValeant Pharma (VRX) Adds to Strong Gains; Sets Sights on $90
November 20, 2015 1:10 PM ESTShort seller target Valeant Pharma (NYSE: VRX) is seeing notably strength again today on the back of yesterday's 16% move up. Shares last traded up 5.6% to $88.73.
Yesterday, Citi endorsed the credit with an Overweight rating and today Mizuho reiterated it as a top pick, saying "the stock appears to have bottomed."
... MoreValeant Pharma (VRX) to Host December 16 Investor Day
November 20, 2015 9:00 AM ESTShort seller target Valeant Pharma (NYSE: VRX) announced it will will be hosting an Investor Day on December 16, 2015 where the Company will be providing updated financial guidance, discussing certain business operations and highlighting certain R&D programs.
Conference Call and Webcast... More
Valeant Pharma (VRX) Surges as Co's Debt Gets Endorsed
November 19, 2015 10:05 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is up 9% early to $79, benefiting from today's Overweight rating on the company's debt at Citi.
The firm cited product diversification and strong FCF generation.
... MoreCiti Credit Research Sees Opportunity in Valeant (VRX), Initiates With Overweight Rating (MNK) (ENDP)
November 19, 2015 9:28 AM ESTCiti Credit Research initiated coverage on Valeant Pharma (NYSE: VRX) with an Overweight rating. Analysts noted its global footprint, product diversification and strong FCF generation. Peers Mallinckrodt (NYSE: MNK) and Endo (NASDAQ: ENDP) were... More
